BioJapan 2026
Pacifico Yokohama
October 7–9, 2026
Meet Genedata experts at BioJapan 2026 and learn how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including analysis and interpretation of data for cell and gene therapy development, screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, stratification of clinical trial subjects, and quality control of biologicals.
Genedata Biologics® streamlines the discovery of biotherapeutics — including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs. As the industry’s most widely adopted platform, it integrates end-to-end workflows and automates routine tasks, empowering teams to focus on scientific innovation.
To schedule a meeting in advance or receive more information in Japanese, please contact .
BioJapan 2026 Organizer Seminar
[G303 ~ G304] AI-Native Antibody Discovery: Integrating Data, Workflows, and Insight
Dr. Mizue Hisano, Scientific Business Consultant, Biologics Business Unit, Genedata AG
Wednesday, October 7 | 1:30 - 3:00 pm JST
Genedata's Dr. Mizue Hisano will be one of the featured speakers in the session "New Modalities × AI-Driven Drug Discovery: Current Landscape and Future," presenting on AI-native antibody discovery and the integration of data, workflows, and scientific insight.
